CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sirnaomics Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sirnaomics Ltd
401 Professional Drive
Suite 280
Gaithersburg, MD  20879  United States Ticker: 22572257

Business Summary
Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2022Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, President, Chief Executive Officer, Founder YangLu 66 1/1/2020 10/15/2020
Group Chief Financial Officer, Vice President - Corporate Finance Wing KeiYip 36 11/15/2022 10/1/2019
Chief Scientific Officer, Executive Director David M.Evans 59 7/12/2021 7/12/2021
11 additional Officers and Directors records available in full report.

Business Names
Business Name
2257
SIRNAOMICS INC.

General Information
Number of Employees: 145 (As of 12/31/2023)
Outstanding Shares: 87,638,480 (As of 12/31/2023)
Stock Exchange: HKG
Email Address: info-office@sirnaomics.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024